[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612633":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":35,"responsibleParty":49,"collaborators":18,"id":52,"slug":18,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":18,"eligibilityCriteria":56,"healthyVolunteers":53,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":18,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":38,"whyStopped":18,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Ain Shams University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"alpha lipoic acid","EXPERIMENTAL","patients will receive alpha lipoic acid 300 mg three times daily under the trade name of THIOTACID manufactured by EVAPHARMA for prophylaxis of the radiation-induced dermatitis (RID) from day 1 of radiation therapy till the end of the study.",[13],"Dietary Supplement: Alpha Lipoic Acid",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","NO_INTERVENTION","patients will not receive any prophylactic intervention as there is no standard of care for prophylaxis to the radiation-induced dermatitis (RID).",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DIETARY_SUPPLEMENT","Alpha Lipoic Acid","alpha lipoic acid 300 mg three times daily under the trade name of THIOTACID manufactured by EVAPHARMA.",[9],[26],{"name":27,"affiliation":28,"role":29},"Rana Mohamed Elsayed Kelany Abdelkader","Faculty of Pharmacy, Ain Shams University","PRINCIPAL_INVESTIGATOR",[31],{"name":27,"role":32,"phone":33,"phoneExt":18,"email":34},"CONTACT","00201023262639","rana.mohamed18@pharma.asu.edu.eg",[36],{"facility":37,"status":38,"city":39,"state":18,"zip":18,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Zagazig University Hospitals","RECRUITING","Zagazig","Egypt",{"type":42,"coordinates":43},"Point",[44,45],31.502,30.58768,{"lat":45,"lon":44},[48],{"name":27,"role":32,"phone":33,"phoneExt":18,"email":34},{"type":29,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Rana mohamed","Principal Investigator","100612633",false,"NCT07256119","Evaluation of the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients","Inclusion Criteria:\n\n* Women aged ≥18 years.\n* Histologically confirmed invasive, early-stage breast carcinoma scheduled for adjuvant radiotherapy.\n* Receiving total radiation dose of 40 Gy for 15 sessions.\n\nExclusion Criteria:\n\n* Prior exposure to radiotherapy.\n* Inflammatory or metastatic breast carcinoma.\n* Patients with connective tissue disorders.\n* Patients with skin inflammatory diseases (e.g. ectopic dermatitis).\n* Patients with known allergy or hypersensitivity to alpha lipoic acid.\n* Concomitant use of nonsteroidal anti-inflammatory drugs, corticosteroids, or antioxidant medications.\n* Patients who will fail to sign the written consent.","FEMALE","18 Years","75 Years",{"count":61,"type":62},40,"ESTIMATED","INTERVENTIONAL",[65],"NA","the purpose of this study is to evaluate the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients",[68],"Prevention",[70,71,22,72],"Radiation Induced Dermatitis","RID","Breast Cancer","2025-12-05",{"date":75,"type":76},"2025-12-12","ACTUAL",{"date":78,"type":76},"2024-08-06",{"date":80,"type":62},"2025-12-28",{"name":5,"class":6},1]